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OBJECTIVE — Oxidative stress plays an important role in the development of microangio-
pathic complications in type 1 diabetes. We investigated polymorphic markers in genes encod-
ing enzymes regulating production of reactive oxygen species in association with diabetic
retinopathy or diabetic nephropathy.
RESEARCH DESIGN AND METHODS — A total of 124 patients with type 1 diabetes
wereinvestigatedinthiscase-controlstudy.Allsubjectswerematchedforsex,age,andduration
ofdiabetes.Genotypingwasconductedusingreal-timePCRforp.Val16Alapolymorphisminthe
MnSODgeneandc.C262TinthepromoterregionoftheCATgene.MultiplexPCRmethodwas
usedfordeterminationofGSTM1andGSTT1polymorphicdeletions.Fluorescence-labeledPCR
amplicons and fragment analysis was used for assessing the number of pentanucleotide
(CCTTT)n repeats in inducible nitric oxide synthase.
RESULTS — ApositiveassociationofMnSODgenotypeVal/Val(oddsratio[OR]2.49,95%CI
1.00–6.16, P  0.045) and GSTM1–1 genotype (2.63, 1.07–6.47, P  0.031) with diabetic
retinopathy but not with diabetic nephropathy was demonstrated. Additionally, the combina-
tionofthetwogenotypesconveyedanevenhigherrisk(4.24,1.37–13.40,P0.009).Noother
investigated genetic polymorphisms were associated with either diabetic retinopathy or diabetic
nephropathy.
CONCLUSIONS — Selected polymorphisms in genes encoding MnSOD and GSTM1 could
be added to a panel of genetic markers for identiﬁcation of individuals with type 1 diabetes at an
increased risk for developing diabetic retinopathy.
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S
everal studies have suggested that
reactive oxygen species (ROS) are
implicated in the etiology of type 1
diabetes (1) as well as in the development
ofseveremicroangiopathiccomplications
such as diabetic retinopathy and diabetic
nephropathy (2). Chronic extracellular
hyperglycemiaindiabetesstimulatesROS
production and increases oxidative stress
(3). The oxidation of high levels of glu-
cose inside diabetic cells produces more
electron donors (NADH and FADH2) and
increases the electron transfer, thereby
generating superoxide (4).
Excess generation of ROS such as su-
peroxide (O2
●), hydrogen peroxide
(H2O2), and hydroxyl radical (
●OH) and
reactivenitrogenspeciessuchasnitricox-
ideoxidizetargetcelularproteins,nucleic
acids, or membrane lipids and damage
their cellular structure and function (4).
Hyperglycemia stimulates the expression
of inducible nitric oxide synthase (iNOS)
and increases production of nitric oxide,
an intracellular second messenger (2). In-
creased nitric oxide generation accompa-
nied by the superoxide overproduction
favors the formation of peroxynitrite, a
highly reactive oxidant (5). Evidence sug-
gests that ROS also regulate the expres-
sion of genes encoding for proteins
involved in inﬂammation, immune re-
sponse, and cell death (6).
Antioxidant enzymes such as manga-
nesesuperoxidedismutase(MnSOD)and
catalase (CAT) directly eliminate ROS,
while glutathione-S-transferases (GSTs)
detoxify cytotoxic secondary metabolites
of ROS. Together they represent a protec-
tive mechanism against the damage
causedbytheoxidativestress.Mostofthe
enzymes involved in the defense against
oxidative stress are polymorphic.
Associations between MnSOD
Val16Alasinglenucleotidepolymorphism
(SNP)anddiabeticnephropathy(7)ordi-
abetic retinopathy in type 2 diabetes (8)
andpolyneuropathyintype1diabetes(9)
emphasize the importance of polymor-
phism in these genes. Individuals carry-
ing the homozygous TT or heterozygous
CTgenotypeinthepromoterregionofthe
CAT gene have signiﬁcantly higher en-
zyme activity, which offers a degree of
protection against development of poly-
neuropathy (10). Human GSTM1 and
GSTT1 polymorphic deletion are associ-
ated with the age of onset of type 1 diabe-
tes (11). Variable expression of the
human iNOS gene polymorphic pen-
tanucleotide (CCTTT)n repeat is associ-
ated with different autoimmune diseases
including type 1 diabetes (12). All de-
scribed polymorphisms could add to the
interindividualvariabilityinpatientswith
type 1 diabetes for the development of
microangiopathic complications.
The aim of our study was to evaluate
the association of polymorphic markers
in genes encoding antioxidant enzymes,
which share a common detoxiﬁcation
pathway (MnSOD, CAT, GSTM1, and
GSTT1) or regulate ROS production
(iNOS) with diabetic retinopathy or dia-
betic nephropathy in a cohort of patients
with type 1 diabetes.
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METHODS— Individuals with type 1
diabetes were recruited from the national
register of childhood-onset type 1 diabe-
tes. Diagnosis of type 1 diabetes was
based on the World Health Organization/
American Diabetes Association deﬁnition
of diabetes (13). All patients were
screenedprospectivelyforthepresenceof
diabeticretinopathybyannualdilatedeye
examination and fundus photography
performed by an ophthalmologist experi-
enced in diagnosing the presence of dia-
betic retinopathy (14). The presence of
diabeticnephropathywasscreenedannu-
ally by assessing microalbuminuria in a
random urine specimen with a dipstick
(Micral-test; Roche Diagnostics, Mann-
heim,Germany)andconﬁrmedifpositive
by the determination of the urine
albumin-to-creatinineratiofromasecond
morning urine specimen. A value of
100 mg/g repeated on at least two of
threemeasurementswasconsidereddiag-
nostic for diabetic nephropathy (15).
The study population consisted of
124 unrelated individuals with type 1 di-
abetes (70 male and 52 female patients,
median age 27.12 years). All patients
were treated with basal-bolus insulin reg-
imen with at least four daily injections or
an insulin pump. They were divided into
two groups: patients with diabetic reti-
nopathyordiabeticnephropathy(n62,
case subjects) and patients without com-
plications after at least 11 years of dura-
tion of type 1 diabetes (n  62, control
subjects). Both groups were matched by
sex, age, and duration of diabetes. The
clinicalcharacteristicsofparticipatingpa-
tients are shown in Table 1. Mean A1C
was calculated from all available values
overtheobservationperiodwithtypically
three to four values per patient annually.
All of the participating patients were of
Caucasian origin and had type 1 diabetes
onset before 16 years of age. Samples for
DNA extraction were obtained during a
routine annual screening for diabetes-
related conditions. This population-
based case-control study was approved
by the National Medical Ethics Commit-
tee. All participating patients gave their
written informed consent.
Materials and methods
Genomic DNA was extracted from pe-
ripheral blood (10 ml) using a FlexiGene
DNA isolation kit (Qiagene, Hilden, Ger-
many) according to the recommended
protocol.
MnSOD and CAT genotyping
For MnSOD Val16Ala polymorphism and
CAT C-262T promoter polymorphism,
real-time PCR genotyping was conducted
on an ABI 7500 Real Time PCR System
(Applied Biosystems, Foster City, CA).
TaqMan SNP Genotyping Assays were
used to determine the regions encom-
passing polymorphic sites. For detection
of Val16Ala (ref. SNP ID: rs4880), assay
ID:C_8709053_10 was used, and for
CAT C-262T (ref. SNP ID: rs1001179),
assay ID:C_11468116_10 was used. The
reaction mixture (5 l) contained 0.125
l TaqMan SNP genotyping assay, 2.5 l
TaqMan Universal PCR Master Mix, and
100 ng extracted genomic DNA. A
thermo-cycling program was performed
according to the manufacturer’s recom-
mendations.
GSTT1 and GSTM1 genotyping
GSTT1 and GSTM1 polymorphic dele-
tions were identiﬁed using a multiplex
PCR-based method with three sets of
primers. For GSTT1 polymorphism, the
sequences of the forward and reverse
primers were 5-ATG TGA CCC TGC
AGTTGC-3and5-GAGATGTGAGGA
CCA GTA AGG AA-3. For GSTM1 poly-
morphic deletion, the forward and re-
verse primers were 5-GCT TCA CGT
GTTATGGAGGTT-3and5-GAGATG
AAG TCC TTC AGA-3. A third set of
primers were 5-GAA GAG CCA AGG
ACA GGT AC-3 and 5-CAA CTT CAT
CCA CGT TCA CC-3 used for co-
ampliﬁcation of the human -globin
gene, an internal control of positive am-
pliﬁcation in the case of the presence of
deletion in both genes. Such genotyping
approach did not allow for detecting het-
erozygous carriers of GSTM1 or GSTT1
deletion; hence, the GSTM1-0 or GSTT1-0
genotype group included only patients
homozygous for GSTM1 or GSTT1 dele-
tion. The GSTM1-1 or GSTT1-1 genotype
group included homozygous and het-
erozygouscarriersofthefunctionalallele.
iNOS genotyping
The iNOS microsatellite marker located
in the promoter region, 2.5 kb upstream
of the transcription start site, was ampli-
ﬁed by PCR combined with ﬂuorescence
labeled primers as described previously
(16).Ampliﬁcationproductsizeswerees-
timated using capillary electrophoresis
with ABI PRISM 310 automated se-
quencer and GeneMapper analysis soft-
ware(AppliedBiosystems,Norwalk,CT).
Allele distribution of pentanucleotide
(CCTTT)n repeats was assessed accord-
ing to the different length of amplicons.
Statistical analysis
SPSS version 16.0 software (SPSS, Chi-
cago, IL) was used. The sample size and
power estimation suggested conventional
statistical methods for comparison be-
tween case and control subjects and 86%
power to detect median size affect (0.3–
0.5) with an  level of 0.05. The null hy-
pothesis that there is no association
between the genotype and the develop-
ment of diabetic retinopathy or diabetic
nephropathyintype1diabeteswastested
for each polymorphic gene locus, and P
values 0.05 were considered statisti-
cally signiﬁcant. Correction for potential
multiple testing errors was performed us-
ing the Bonferroni method. Testing for
deviation from Hardy-Weinberg equilib-
rium (HWE) using an HWE calculator
was performed, and observed genotype
frequencies of the studied polymor-
phisms were in agreement with HWE
(	
2  0.291, P  0.864 for MnSOD and
	
2  0.828, P  0.363 for GSTM1).
An independent t test was performed
to compare the continuous parameters
between case and control subjects. Lev-
Table1—Characteristicsofpatientswithtype1diabeteswithchroniccomplications(diabetic
retinopathy or diabetic nephropathy case subjects) and without chronic complications
(control subjects)
Control subjects Case subjects P
n 62 62
Age (years) 26.8 
 5.5 27.4 
 5.8 0.072
Sex (M/F) 35/27 35/27 —
Age at onset (years) 8.5 
 4.4 7.3 
 3.4 0.257
Duration of diabetes (years) 17.9 
 5.6 19.3 
 5.8 0.087
Mean A1C 8.1 
 1.1 8.2 
 1.0 0.748
Data are means 
 SD unless otherwise indicated. Patient groups were matched by sex, age, age at onset, and
durationofdiabetes.Pvaluesarearesultofthettestforcomparisonofcontinuousparametersbetweenboth
groups.
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gested which statistical analysis is more
appropriate and which P value should be
considered. Genotype and allele frequen-
cies between study groups were com-
pared by Pearson 	
2 and/or Fisher exact
test. Strength of association between
polymorphisms in genes encoding anti-
oxidant enzymes and development of
complication in diabetes was estimated
using odds ratios (ORs) and 95% CI. The
binary logistic regression analysis was ap-
plied to check on the calculated ORs, ad-
justed for independent variables such as
age, sex, age at onset, and duration of
diabetes.
RESULTS— Clinical characteristics of
patients are presented in Table 1. No sig-
niﬁcant differences were observed be-
tween both groups regarding age, age at
onset, duration of diabetes, or mean A1C.
The MnSOD genotype Val/Val was
signiﬁcantly more frequent in patients
with diabetic retinopathy, carrying a
2.49-fold higher risk for development of
diabetic retinopathy (OR 2.49, 95% CI
1.00–6.16, P  0.045) (Table 2). Geno-
type GSTM1-1 was signiﬁcantly more
frequentinpatientswithdiabeticretinop-
athy, carrying a 2.63-fold higher risk for
the development of diabetic retinopathy
(OR2.63,95%CI1.07–6.47,P0.031)
(Table 2). Results of the Pearson 	
2 test
revealed no signiﬁcant differences in al-
lele and genotype frequencies for CAT
andGSTT1polymorphismsinassociation
with diabetic retinopathy or diabetic ne-
phropathy.
Nine alleles for the iNOS microsatel-
lite ranging from 176 to 216 bp (8–16
pentanucleotide repeats) were observed
(Table 3). No signiﬁcant difference in
overall allelic distribution was detected
between patients with diabetic retinopa-
thy versus control subjects (	
2  1.738,
df  8, P  0.988) or between patients
with diabetic nephropathy versus control
subjects(	
27.736,df8,P0.460).
Allele196(12repeatallele)provedtobethe
mostfrequentalleleinourstudypopulation
(31.2%ofallobservedalleles).Wedetected
slightly increased risk for diabetic retinopa-
thyinpatientscarryingallele196(OR2.19,
95% CI 0.88–5.49, P  0.089), but it did
not reach statistical signiﬁcance.
Interaction between different geno-
types in genes encoding for antioxidant
enzymes was investigated (Table 4). The
carriers of both GSTM1-0 and GSTT1-0
null genotypes, which result in a com-
pletelackofenzymeactivity,didnothave
an increased risk for development of mi-
croangiopathic complication in type 1 di-
abetes. Patients with a combination of
MnSOD Val/Val genotype and GSTM1-1
normal genotype had signiﬁcantly higher
Table 3—Allele frequencies of iNOS (CCTTT)n gene polymorphism in patients with type 1
diabetes with diabetic retinopathy or diabetic nephropathy and control subjects
Number of
(CCTTT)
repeats
Size
(base pairs)
Diabetic
retinopathy
subjects (%)
Control
subjects
(%)
Diabetic
nephropathy
subjects (%)
Control
subjects
(%)
8 176 1.8 1.6 0 2.4
9 181 3.6 3.3 1.4 4.2
10 186 10.7 13.6 12.2 13.3
11 191 19.6 23.4 31.1 18.7
12* 196 35.7 29.9 29.7 31.9
13 201 16.1 17.4 16.2 17.5
14 206 8.9 8.2 8.1 8.4
15 211 3.6 2.2 1.4 3.0
16 216 0 0.5 0 0.6
Four patients were excluded from the analysis because of insufﬁcient PCR ampliﬁcation of the iNOS
microsatellitelocus.PvaluesaretheresultofPearson	
2testcomparingalleleversusalltheotheralleles.*OR
2.19, 95% CI 0.88–5.49, P  0.089.
Table 2—Genotype frequencies of MnSOD, GSTM1, GSTT1, and CAT polymorphisms in patients with type 1 diabetes with retinopathy or
nephropathy
Diabetic
retinopathy,
control 32/92
(%) P OR 95% CI
Diabetic
nephropathy,
control 37/87
(%) P OR 95% CI
MnSOD
Genotype Ala/Ala 18.8/28.3 0.290 1.71 0.63–4.63 18.9/28.7 0.253 1.73 0.67–4.45
Genotype Ala/Val 46.9/54.3 0.530 0.77 0.34–1.74 62.2/48.3 0.157 1.76 0.80–3.86
Genotype Val/Val 34.4/17.4 0.045 2.49 1.00–6.16 18.9/23.0 0.615 0.78 0.30–2.05
CAT
Genotype CC 64.5/52.7 0.255 0.61 0.26–1.43 62.2/52.9 0.346 0.68 0.31–1.51
Genotype CT 32.3/41.8 0.35 0.66 0.28–1.57 32.4/42.4 0.303 0.65 0.29–1.47
Genotype TT 3.2/5.5 0.614 1.74 0.19–15.54 5.4/4.7 0.870 0.86 0.15–4.94
GSTM1
Genotype GSTM1-1 75.0/46.7 0.031 2.63 1.07–6.47 59.5/58.6 0.931 1.03 0.47–2.26
Genotype GSTM1-0 25.0/53.3 — 1.00 40.5/41.4 — 1.00
GSTT1
Genotype GSTT1-1 81.2/75.0 0.472 1.44 0.53–3.95 81.1/74.7 0.443 1.45 0.56–3.76
Genotype GSTT1-0 18.8/25.0 — 1.00 18.9/25.3 — 1.00
ORs and 95% CIs were calculated from a cross-tabulation 2  2 table and risk estimate of one genotype versus the rest of all other genotypes comparing patients
with type 1 diabetes with diabetic retinopathy or diabetic nephropathy and those without diabetic retinopathy or diabetic nephropathy.
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this particular combination (OR 4.24,
95% CI 1.37–13.40, P  0.009).
CONCLUSIONS — We hypothe-
sized that genetic variability of enzymes
regulating oxidative stress could be in-
volved in development of microangio-
pathic complications in people with type
1 diabetes.
The MnSOD Val/Val genotype was as-
sociated with a 2.49-fold higher risk for di-
abetic retinopathy in our cohort of patients
withtype1diabetes.Val/Valgenotypecom-
bined with smoking is associated with dia-
betic nephropathy in type 1 diabetes (7).
WedidnotﬁndanassociationbetweenVal/
Val and diabetic nephropathy in our cohort
of patients with type 1 diabetes where none
reported smoking. MnSOD Val16Ala poly-
morphism is also associated with diabetic
retinopathy (8) and diabetic nephropathy
(17)intype2diabetes.Invitrostudiesshow
that amino acid substitution of Ala with Val
modiﬁes helical structure of the signal se-
quenceandalterstheimportofMnSODen-
zyme into the mitochondrial matrix (18).
LessefﬁcientimportdecreasesMnSODcon-
centration inside mitochondria and results
in overproduction of superoxide, which is
considered to be a causal link between hy-
perglycemia and metabolic pathways in-
volvedinvascularcomplicationsindiabetes
(4).Studiesonmice,treatedwithstreptozo-
tocin, show that MnSOD overexpression in
mitochondria play a signiﬁcant protective
role in development of diabetic retinopathy
(19).
A signiﬁcant association between the
presence of the functional GSTM1 gene
and development of diabetic retinopathy
wasobservedinourstudy.Thissuggested
that deletion in the GSTM1 gene had a
protective role for diabetic retinopathy. A
large number of studies on GSTM1-0
and/or GSTT1-0 null genotypes report an
increased risk for development and pro-
gression of rheumatoid arthritis and
asthma (20,21). However, one study re-
ports an association of GSTM1 gene dele-
tionwithprotectionfromdevelopmentof
type 1 diabetes in a group of 14- to 20-
year-old children (11). The protective
roleofGSTM1nullgenotypeinthedevel-
opment of diabetic retinopathy in type 1
diabetes has, to the best of our knowl-
edge, not been described yet. One possi-
ble explanation for the protective role is
that the absence of the GSTM1 gene may
upregulate other antioxidant enzymes in-
cludingMnSOD(22).However,allexpla-
nations are speculative and need to be
conﬁrmed in further studies.
When studying the synergistic effect
of different polymorphisms, we observed
a4.24-foldhigherriskfordevelopmentof
diabetic retinopathy in patients with type
1 diabetes carrying the MnSOD Val/Val
andnormalGSTM1-1genotype.Evidence
of interaction between MnSOD and GST
genes is reported in a case-control study
of rheumatoid arthritis (23) but to our
knowledge has not been described in pa-
tients with type 1 diabetes and diabetic
retinopathy.
The association studies that evaluate
the impact of genotype on disease pro-
gression are usually limited by the fact
that more chronic complications will de-
velop with longer follow-up. Considering
that the duration of diabetes is an impor-
tantriskfactorformicroangiopathiccom-
plications,ourresultsmustbeinterpreted
withcaution.Inmostpatientswithtype1
diabetes, the earliest signs of diabetic
complicationsoccurafter5–10years,and
the highest incidence (between 75 and
95%) occur after 10 years (24). Control
subjects in our study were without dia-
betic complications for a mean of 17.9
years after the onset of type 1 diabetes.
Another limitation of our study was a rel-
atively small number of participants.
However, the studied population was ho-
mogenous,andpowerestimationshowed
that our study had an 86% power to de-
tect median size affect (0.3–0.5) with an
 level of 0.05.
Other genetic polymorphisms in-
volved in the hyperglycemia-induced cell
damage could inﬂuence our results. No-
tably, advanced glycation end products
modify ROS formation through advanced
glycation end product receptors and
therefore inﬂuence the production of
growth factors and cytokines by affected
cells(4).Ourresultsthusrepresentonlya
part of the complex pathobiologic net-
work of diabetic retinopathy or diabetic
nephropathy.
Finally, poor glycemic control in-
creases the risk for diabetic nephropathy
or diabetic retinopathy. Moreover, a lim-
ited period of poor glycemic control can
have a prolonged effect on the incidence
of diabetic retinopathy (“metabolic mem-
ory”) as demonstrated by the Epidemiol-
ogy of Diabetes Interventions and
Complications (EDIC) cohort follow-up
(25). Our groups with and without dia-
betic retinopathy had similar mean A1C.
However, possible periods of poor glyce-
mic control in individual patients during
the observation period could inﬂuence
our results.
Inconclusion,wefoundastatistically
signiﬁcant association between MnSOD
Val/Val and GSTM1-1 genotype and de-
velopment of diabetic retinopathy in type
1 diabetes. To the best of our knowledge,
this is the ﬁrst study reporting a positive
association of a normal GSTM1-1 geno-
type with development of a microangio-
pathic complication in type 1 diabetes.
Additionally, a combination of both
MnSOD Val/Val and GSTM1-1 genotypes
further increased the risk for diabetic ret-
inopathy. Testing for genetic markers in
genes encoding antioxidant enzymes ei-
ther individually or in combination could
beaddedtoageneticpanelforidentifying
patients at higher risk for developing dia-
betic retinopathy in clinical practice.
Table 4—Genotype frequencies for gene–gene interactions between patients with type 1
diabetes with retinopathy or without retinopathy (control subjects)
Diabetic
retinopathy
subjects,
n  32 (%)
Control
subjects,
n  92
(%) P OR 95% CI
GSTM1–1 and GSTT1–1
Carriers 53.1 35.9 0.087 2.03 0.89–4.58
Noncarriers 46.9 64.1
MnSOD Val/Val and GSTM1–1
Carriers 41.7 14.3 0.009 4.24 1.37–13.40
Noncarriers 58.3 85.7
MnSOD Val/Val and GSTT1–1
Carries 30.8 17.4 0.154 2.11 0.75–5.97
Noncarriers 69.2 82.6
ORs and 95% CIs were calculated from cross-tabulation 2  2 table composing carrier versus noncarrier of
particular genotype among patients with type 1 diabetes with retinopathy and without retinopathy.
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